Henry Schein stock (US42548G1040): valuation metrics in focus after steady Nasdaq trading

Henry Schein shares were little changed in recent Nasdaq trading, keeping the U.S. dental and medical distributor in a mid-teen earnings multiple range as investors weigh its latest quarterly numbers and cash-generation profile.

Henry Schein shares on the Nasdaq Global Select Market traded in the mid-70 USD range this week, leaving the New York-listed healthcare distributor broadly flat over the past few sessions as investors digest its most recent earnings report and guidance for 2026, according to Nasdaq price data as of late May 2026.

The stock, which trades under the ticker HSIC in the United States, most recently changed hands at around USD 75 on 05/28/2026, after moving between an intraday low near USD 74.70 and a high just under USD 76, based on Nasdaq trading statistics reported that day.

This places the company’s equity value in the high single-digit billion dollar range and implies a price-to-earnings ratio in the low 20s on trailing earnings, positioning Henry Schein at a valuation premium to some broad healthcare distribution benchmarks but within the range for defensive, service-focused medical suppliers.

From a home-country perspective, the United States remains the central reference point for the stock, with U.S. investors watching both sector dynamics in dental and medical supply markets and broader movements in indices such as the S&P 500 and Nasdaq Composite when assessing sentiment toward HSIC.

On German trading venues such as Tradegate, Henry Schein is also accessible to European retail investors in euro, with quotations reflecting the underlying U.S. price converted at prevailing exchange rates, although liquidity and volumes remain concentrated on the Nasdaq listing in the United States.

Market participants have spent recent weeks parsing the company’s latest quarterly update, which outlined revenue trends in its dental distribution, medical distribution, and technology and value-added services operations, as well as management’s comments on margin resilience in an environment of cost inflation and shifting demand patterns across dental practices and outpatient medical facilities.

Following that earnings release, attention has shifted toward how effectively Henry Schein can balance investments in technology platforms and practice-management solutions with disciplined cost control, in order to sustain earnings growth that supports its current valuation multiples.

In the regulatory arena, the company continues to report insider and executive shareholdings through filings with the U.S. Securities and Exchange Commission, underscoring standard corporate-governance practices for a U.S.-listed healthcare distributor.

One such filing in May 2026 detailed the equity interests of a senior executive, including common shares, restricted stock units, and stock options granted under long-term incentive plans, providing investors with transparency into management’s alignment with shareholder interests.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Henry Schein
• Sector/industry: Healthcare distribution and dental/medical supplies
• Headquarters/country: Melville, United States
• Core markets: North America, Europe, and selected international dental and medical markets
• Key revenue drivers: Dental and medical distribution, consumables and equipment sales, and technology and value-added practice solutions
• Home exchange/listing venue: Nasdaq Global Select Market (HSIC)
• Trading currency: USD

Henry Schein: core business model

Henry Schein operates as a global distributor of dental and medical products while also providing software and other value-added services that help healthcare practices manage clinical workflows, procurement, and business operations, with revenue primarily generated from recurring consumables, equipment sales, and technology subscriptions.

Valuation metrics and multiples for Henry Schein

With Henry Schein trading in the mid-70 USD area in late May 2026, the company’s share price reflects a market capitalization in the high single-digit billions and equates to a trailing price-to-earnings multiple in the low 20s, a range that situates HSIC above many broad-market indices but still within typical bands for established healthcare distributors with stable cash flows.

Investors tracking the stock frequently compare its valuation to those of listed peers in the dental and medical supply space, looking at indicators such as enterprise-value-to-EBITDA, free-cash-flow yield, and the relationship between earnings growth expectations and the current earnings multiple, while also considering Henry Schein’s modest dividend profile and share-repurchase activity when evaluating total-return potential at today’s price.

Conclusion

Henry Schein’s recent trading on the Nasdaq in the mid-70 USD range keeps the U.S. healthcare distributor in a valuation corridor that implies investor confidence in its ability to deliver steady earnings and cash flow. With a trailing earnings multiple in the low 20s, the market is assigning a moderate premium that appears linked to the company’s mix of recurring consumable sales and technology-enabled services. How Henry Schein executes on its growth initiatives and cost-management plans across dental and medical markets will be crucial in determining whether the current valuation range remains sustainable over the coming quarters.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.